Comparative Pharmacology
Head-to-head clinical analysis: DULERA versus FLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DULERA versus FLAC.
DULERA vs FLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DULERA is a combination of formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, a corticosteroid. Formoterol acts by relaxing bronchial smooth muscle via beta2-receptor activation. Mometasone furoate reduces inflammation in the lungs by inhibiting inflammatory mediators and suppressing immune responses.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
Inhalation: 2 inhalations twice daily (morning and evening). Each inhalation delivers mometasone furoate 100/200 mcg and formoterol fumarate 5 mcg.
Adults: 40 mg orally twice daily.
None Documented
None Documented
Formoterol: terminal half-life 10-14 hours (supports twice-daily dosing); Mometasone: terminal half-life 13.8 hours (range 10-20 hours) after inhalation.
2-4 hours; prolonged in renal impairment (up to 12 hours)
Formoterol: 10-15% renal as unchanged drug and metabolites, remainder hepatically cleared; Mometasone: >99% biliary/fecal as metabolites, <1% renal unchanged.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Category C
Category C
Corticosteroid/Beta2-Agonist Combination
Corticosteroid